Medicalgorithmics S.A.

Capital/Financing Update • Apr 15, 2025

Report Content Subject:Amendmentand Execution of Loan Agreements with BioFundCurrent Report No.:5/2025Date of preparation:April 15, 2025Legal basis:Article 17(1) of Regulation (EU) No 596/2014 of the European Parliamentand of the Council (MAR) - inside information

The Management Board of Medicalgorithmics S.A., withits registered office in Warsaw (the "Company"), hereby announces thaton April 15, 2025, it entered into a loan agreement with the Company'sshareholder - BioFund Capital Management LLC ("BioFund") - for a maximumprincipal amount in United States dollars (USD) equivalent to PLN9,000,000.00, payable in four tranches (the "Agreement").

The tranches will be disbursed, upon the Company'srequest, by the 15th day of each month from July 2025 to October 2025.The disbursement of each tranche is conditional upon the establishmentof collateral. The loan shall bear interest at a fixed rate of 14%. Theloan shall be repaid in 45 equal principal and interest installments inaccordance with a repayment schedule, commencing on October 31, 2026,and ending on June 30, 2030. Repayment of the loan shall be made in USD.

The collateral for the claims arising under theAgreement is the Company's declaration of voluntary submission toenforcement pursuant to Article 777 §1 point 5 of the Polish Code ofCivil Procedure, up to the amount of USD 6,000,000, from its entireassets.

Should the Company make full or partial prepayment ofany loan installment before the due date specified in the repaymentschedule, BioFund shall be entitled to a fee of 10% (per annum) of theproduct of the prepayment amount and the number of days remaining untilthe scheduled repayment date as specified in the Agreement (the "Fee").

The occurrence of an event of default shallconstitute grounds for: BioFund's demand for early repayment of the fullamount of the disbursed loan together with accrued interest within 90business days from the receipt of such demand (and to cease any furtherdisbursement of loan amounts in the future), and the payment of the Feeby the Company. Events of default include, inter alia: (i) entry into afinancing agreement without BioFund's consent, other than one concludedup to the maximum principal amount, on more favorable financial terms;(ii) failure to implement the financial plan; (iii) failure to establishthe required collateral; (iv) disposal of assets without BioFund'sconsent.

In the event a third party acquires more than 50% ofthe shares in the Company's share capital (a change of control), BioFundshall have the right to demand repayment of the full amount of thedisbursed loan together with accrued interest and to cease any futureloan disbursements, within 90 business days from the date the Companyreceives such demand. In the event of repayment demand due to a changeof control, BioFund shall also be entitled to receive the Fee.

Simultaneously, the Management Board announces thatthe Company has executed an annex with BioFund to the loan agreementdisclosed by the Company in Current Report No. 24/2024, which amendedthe loan repayment schedule. Pursuant to the new provisions, the Companyhas undertaken to repay the entire loan, together with all accruedinterest and any other amounts due under the Agreement, in 30 equalprincipal and interest installments, payable from October 31, 2026,through March 31, 2029. Additionally, in the event a third partyacquires more than 50% of the shares in the Company's share capital (achange of control), BioFund shall have the right to demand repayment ofthe full amount of the disbursed loan together with accrued interest andto cease any future loan disbursements, within 90 business days from thedate the Company receives such demand; however, BioFund shall not beentitled to the Fee in this case.